Effect of statin therapy on colorectal cancer

Bardou, Marc; Barkun, Alan N.; Martel, Myriam

doi:10.1136/gut.2009.190900

Cited by 151 publications

(140 citation statements)

References 117 publications

(76 reference statements)

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…Eine aktuelle Metaanalyse von Fallkontroll-, Kohorten-und randomisierten Studien belegt einen statistisch signifikanten, aber nur geringen Effekt von Statinen in der Primärprävention des kolorektalen Karzinoms [83]. In einer Phase-III-Studie zur Sekundärprävention von Kolonadenomen senkte Ursodesoxycholsäure signifikant nur das Risiko für Adenome mit hochgradigen Dysplasien, aber nicht für Adenome insgesamt [90].…”

Section: Hintergrundunclassified

S3-Leitlinie – Kolorektales Karzinom

Schmiegel

Buchberger

Follmann³

et al. 2017

Z Gastroenterol

147

View full text Add to dashboard Cite

Section: Hintergrundunclassified

S3-Leitlinie – Kolorektales Karzinom

Schmiegel

Buchberger

Follmann³

et al. 2017

Z Gastroenterol

147

View full text Add to dashboard Cite

“…In allen drei Studien zeigte sich jedoch eine deutlich erhöhte kardiovaskuläre Morbidität. Eine aktuelle Metaanalyse von Fallkontroll-, Kohorten-und randomisierten Studien belegt einen statistisch signifikanten, aber nur geringen Effekt von Statinen in der Primärprävention des kolorektalen Karzinoms [82]. In einer Phase-III-Studie zur Sekundärprävention von Kolonadenomen senkte Ursodesoxycholsäure signifikant nur das Risiko für Adenome mit hochgradigen Dysplasien, aber nicht für Adenome insgesamt [89].…”

Section: Gcp Konsensunclassified

S3-Leitlinie Kolorektales Karzinom Version 1.0 - Juni 2013 AWMF-Registernummer: 021/007OL

et al. 2013

View full text Add to dashboard Cite

“…The anticancer effect of statins is the subject of numerous investigations, several results have reported efficacy of HMG-CoA reductase inhibitors against various types of cancer as leukemia, prostate, lung, colorectal and breast (Sławińska and Kandefer-Szerszeń, 2008;Bardou et al, 2010;Papadopoulos et al, 2011). PPARγ agonists demonstrate mechanisms of suppression of tumor development in several in vitro and in vivo models.…”

Section: Introductionmentioning

confidence: 99%

Synergistic anticancer effects of valproic acid, atorvastatin and pioglitazone in human malignant and murine cells

Andr¹,

Jaciana²,

Larissa³

et al. 2014

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

Valproic acid, atorvastatin and pioglitazone belong to different therapeutic drug classes and exhibit biological activities that are capable of interfering with cancer development. In this study, we examined the anticancer synergistic effects of these three drugs in experimental models in vitro and in vivo. Cytotoxic activity was determined against K562, NCI-H292 and HEp-2 lines cells. The Ehrlich carcinoma was used as in vivo model. Atorvastatin associated with pioglitazone, presented cytotoxicity against NCI-H292 cells with IC 50 value 3.75 µg/ml. The ultra-structural analysis showed that the atorvastatin in combination with pioglitazone induced apoptosis in 66.3% of the cells. Treatment with either valproic acid or valproic acid + atorvastatin + pioglitazone presented cytotoxicity in Ehrlich carcinoma cells, with IC 50 values equal to 10.8 and 11.4 µg/ml, respectively. In evaluation of antitumor effects in vivo it was observed that valproic acid or the atorvastatin + pioglitazone induced tumor inhibition of 60.2 and 64.9%, respectively. However, histopathology analysis suggests that the liver and kidneys are affected by both treatments. In conclusion, the data indicate that atorvastatin + pioglitazone present synergistic anticancer effect in lung cancer cells and solid tumours.

show abstract

Effect of statin therapy on colorectal cancer

Cited by 151 publications

References 117 publications

S3-Leitlinie – Kolorektales Karzinom

S3-Leitlinie – Kolorektales Karzinom

S3-Leitlinie Kolorektales Karzinom Version 1.0 - Juni 2013 AWMF-Registernummer: 021/007OL

Synergistic anticancer effects of valproic acid, atorvastatin and pioglitazone in human malignant and murine cells

Contact Info

Product

Resources

About